Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

Home/Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

Therapeutic, Pharmaceutical Manufacturing, Pharmacy, Pharma & Healthcare

Publication ID:

GBI0318005

Publication Date:

March 31, 2018

Pages:

181

Publisher:

GBI Research

Region:

Global

$4,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

Summary

Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations.

Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response.

This report covers all immunological disorders, but there is a particular focus on four key diseases, rheumatoid arthritis, psoriasis, inflammatory bowel disease and graft versus host disease/transplant rejection, as these conditions have the largest pipelines within the therapy area.

The market size for immunology therapeutics was valued at $65.1 billion in 2016 and it is expected to grow at a compound annual growth rate (CAGR) of 8.2% to $113 billion in 2023.

Scope

- The immunology market landscape is expected to change. Biosimilar competition is expected to affect the revenue of the big blockbuster drugs, and novel targets are expected to enter the market and drive market growth.
- Overall, there are 2,070 immunology products in the pipeline.
- Which molecular targets are most prominent within the pipeline?
- How do the key indications differ in terms of molecule type?
- How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action are most common for pipeline drugs?
- The market size for immunology therapeutics is expected to grow, from $65.1 billion in 2016 to $113 billion in 2023, at a CAGR of 8.2%.
- Which products will contribute to market growth most, and which will achieve blockbuster status?
- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
- What CAGR will these companies register in the forecast period?
- How many strategic consolidations have been completed in the past decade?
- Which types of assets attract the largest deal values?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
- Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
- Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
- Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
- Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
- Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 12
2.1 Therapy Area Overview 12
2.1.1 Rheumatoid Arthritis 12
2.1.2 Psoriasis 13
2.1.3 Inflammatory Bowel Disease 14
2.1.4 Graft Versus Host Disease and Transplant Rejection 15
2.2 Symptoms 16
2.3 Diagnosis 19
2.3.1 Rheumatoid Arthritis 19
2.3.2 Psoriasis 19
2.3.3 Inflammatory Bowel Disease 19
2.3.4 Graft Versus Host Disease and Transplant Rejection 20
2.4 Etiology and Pathophysiology 20
2.4.1 Rheumatoid Arthritis 23
2.4.2 Psoriasis 24
2.4.3 Inflammatory Bowel Disease 25
2.4.4 Graft Versus Host Disease and Transplant Rejection 26
2.5 Epidemiology 27
2.5.1 Rheumatoid Arthritis 28
2.5.2 Psoriasis 28
2.5.3 Inflammatory Bowel Disease 29
2.5.4 Graft Versus Host Disease and Transplant Rejection 31
2.6 Co-morbidities and Complications 31
2.7 Treatment 32
2.7.1 Rheumatoid Arthritis 33
2.7.2 Psoriasis 35
2.7.3 Inflammatory Bowel Disease 36
2.7.4 Graft-Versus-Host Disease and Transplant Rejection 37
3 Key Marketed Products 40
3.1 Overview 40
3.2 Humira (adalimumab) - AbbVie 41
3.3 Enbrel (etanercept) - Amgen 43
3.4 Remicade (infliximab) - Johnson & Johnson 45
3.5 Rituxan (rituximab) - Roche 48
3.6 Stelara (ustekinumab) - Johnson & Johnson 50
3.7 Simponi (golimumab) - Johnson & Johnson 52
3.8 Orencia (abatacept) - Bristol-Myers Squibb 54
3.9 Tysabri (natalizumab) - Biogen 56
3.10 Actemra (tocilizumab) - Roche 58
3.11 Prograf (tacrolimus) - Astellas 60
3.12 Cimzia (certolizumab) - UCB 62
3.13 Entyvio (vedolizumab) - Takeda 64
3.14 Cosentyx (secukinumab) - Novartis 65
3.15 Otezla (apremilast) - Celgene 67
3.16 Xeljanz (tofacitinib) - Pfizer 68
3.17 Taltz (ixekizumab) - Eli Lilly 70
4 Pipeline Landscape Assessment 72
4.1 Overview 72
4.2 Pipeline Development Landscape 72
4.3 Molecular Targets in the Pipeline 76
4.4 Clinical Trials Landscape 79
4.4.1 Clinical Trial Failure Rates 80
4.4.2 Clinical Trial Duration 82
4.4.3 Clinical Trial Size 86
4.4.4 Cumulative Clinical Program Size 90
4.5 Assessment of Key Late-Stage Pipeline Products 93
4.5.1 Filgotinib - Galapagos and Gilead Sciences 93
4.5.2 AR-101 - Aimmune Therapeutics 94
4.5.3 Upadacitinib tartrate - AbbVie 95
4.5.4 Lanadelumab - Shire 97
4.5.5 Ozanimod hydrochloride - Celgene 98
4.5.6 Risankizumab - AbbVie 99
4.6 Conclusion 101
5 Multi-scenario Market Forecast to 2023 102
5.1 Overall Market Size 102
5.2 Generic Penetration 104
5.3 Revenue Forecast by Molecular Target 105
5.3.1 Cytokines and Cytokine Receptors 106
5.3.2 Intracellular Signal Transducers 107
5.3.3 Cell Surface Antigens 108
5.3.4 Intercellular Interaction and Adhesion Molecules 109
6 Company Analysis and Positioning 111
6.1 Revenue and Market Share Analysis by Company 113
6.1.1 AbbVie 118
6.1.2 Johnson & Johnson 119
6.1.3 Novartis 120
6.1.4 Pfizer 122
6.1.5 Roche 123
6.1.6 Amgen 124
6.1.7 Celgene 125
6.1.8 Eli Lilly 126
6.2 Company Landscape 127
6.3 Marketed and Pipeline Portfolio Analysis 128
7 Strategic Consolidations 131
7.1 Licensing Deals 131
7.1.1 Deals by Region, Year and Value 131
7.1.2 Deals by Indication 132
7.1.3 Deals by Stage of Development 133
7.1.4 Deals by Molecule Type, Molecular Target and Value 134
7.1.5 Table for Licensing Deals with Disclosed Values 135
7.2 Co-development Deals 138
7.2.1 Deals by Region, Year and Value 138
7.2.2 Deals by Indication 139
7.2.3 Deals by Stage of Development 140
7.2.4 Deals by Molecule Type, Molecular Target and Value 141
7.2.5 Table for Co-development Deals with Disclosed Values 142
8 Appendix 144
8.1 References 144
8.2 Figures of All Clinical Stage Pipeline Products 157
8.3 Abbreviations 177
8.4 Disease List 178
8.5 Methodology 178
8.5.1 Coverage 179
8.5.2 Secondary Research 179
8.5.3 Market Size and Revenue Forecasts 179
8.5.4 Pipeline Analysis 180
8.5.5 Competitive Landscape 180
8.6 Contact Us 180
8.7 Disclaimer 181

List of Tables
1.1 List of Tables
Table 1: Immunology Drugs Market, Global, Symptoms of RA, Psoriasis and IBD, 2018 17
Table 2: Immunology Drugs Market, Global, Organ-Specific Symptoms of Transplant Rejection, 2018 18
Table 3: Immunology Drugs Market, Global, Organ-Specific Symptoms of Acute GVHD, 2018 18
Table 4: Immunology Drugs Market, Global, Organ-Specific Symptoms of Chronic GVHD, 2018 19
Table 5: Immunology Drugs Market, Etiology of RA, Psoriasis, IBD and GVHD, 2018 21
Table 6: Immunology Drugs Market, 7MM, Epidemiology of Key Immunology Indications, 2018 27
Table 7: Immunology Drugs Market, Global, Approved Indications for Humira, 2018 41
Table 8: Immunology Drugs Market, Global, Approved Indications for Enbrel, 2018 44
Table 9: Immunology Drugs Market, Global, Approved Indications for Remicade, 2018 46
Table 10: Immunology Drugs Market, Global, Approved Indications for Rituxan, 2018 49
Table 11: Immunology Drugs Market, Global, Approved Indications for Stelara, 2018 51
Table 12: Immunology Drugs Market, Global, Approved Indications for Simponi, 2018 53
Table 13: Immunology Drugs Market, Global, Approved Indications for Orencia, 2018 55
Table 14: Immunology Drugs Market, Global, Approved Indications for Tysabri, 2018 57
Table 15: Immunology Drugs Market, Global, Approved Indications for Actemra, 2018 59
Table 16: Immunology Drugs Market, Global, Approved Indications for Prograf, 2018 61
Table 17: Immunology Drugs Market, Global, Approved Indications for Cimzia, 2018 62
Table 18: Immunology Drugs Market, Global, Approved Indications for Entyvio, 2018 64
Table 19: Immunology Drugs Market, Global, Approved Indications for Cosentyx, 2018 66
Table 20: Immunology Drugs Market, Global, Approved Indications for Otezla, 2018 67
Table 21: Immunology Drugs Market, Global, Approved Indications for Xeljanz, 2018 69
Table 22: Immunology Drugs Market, Global, Approved Indications for Taltz, 2018 70
Table 23: Immunology Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023 103
Table 24: Immunology Drugs Market, Global, Usage of Generics Across Key Indications, 2018 105
Table 25: Immunology Drugs Market, Global, Forecast Revenue by Company (%), 2016-2023 113

List of Figures
1.2 List of Figures
Figure 1: Immunology Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2016-2023 28
Figure 2: Immunology Drugs Market, 7MM, Epidemiology Patterns for Psoriasis, 2016-2023 29
Figure 3: Immunology Drugs Market, 7MM, Epidemiology Patterns for Crohn’s Disease, 2016-2023 30
Figure 4: Immunology Drugs Market, Epidemiology Patterns for Ulcerative colitis, 2016-2023 30
Figure 5: Immunology Drugs Market, Epidemiology Patterns for Graft Versus Host Disease, 2016-2023 31
Figure 6: Immunology Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 40
Figure 7: Immunology Drugs Market, Global, Annual Revenues for Humira ($bn), 2006-2023 43
Figure 8: Immunology Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006-2023 45
Figure 9: Immunology Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006-2023 48
Figure 10: Immunology Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2023 50
Figure 11: Immunology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010-2023 52
Figure 12: Immunology Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010-2023 54
Figure 13: Immunology Drugs Market, Global, Annual Revenue for Orencia ($bn), 2006-2023 56
Figure 14: Immunology Drugs Market, Global, Annual Revenue for Tysabri ($bn), 2006-2023 58
Figure 15: Immunology Drugs Market, Global, Annual Revenues for Actemra ($bn), 2006-2023 60
Figure 16: Immunology Drugs Market, Global, Annual Revenue for Prograf ($bn), 2006-2023 62
Figure 17: Immunology Drugs Market, Global, Annual Revenue for Cimzia ($bn), 2008-2023 63
Figure 18: Immunology Drugs Market, Global, Annual Revenue for Entyvio ($bn), 2014-2023 65
Figure 19: Immunology Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015-2023 66
Figure 20: Immunology Drugs Market, Global, Annual Revenue for Otezla($bn), 2014-2023 68
Figure 21: Immunology Drugs Market, Global, Annual Revenues for Xeljanz ($bn), 2012-2023 70
Figure 22: Immunology Drugs Market, Global, Annual Revenue for Taltz ($bn), 2016-2023 71
Figure 23: Immunology Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 72
Figure 24: Immunology Drugs Market, Global, Pipeline by Stage of Development and Molecule Type, 2018 73
Figure 25: Immunology Drugs Market, Global, Pipeline by Program Type, 2018 74
Figure 26: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Stage of Development, 2018 75
Figure 27: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Molecule Type, 2018 76
Figure 28: Immunology Drugs Market, Pipeline by Molecular Target, 2018 78
Figure 29: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Molecular Target, 2018 79
Figure 30: Immunology Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006-2018 80
Figure 31: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006-2017 81
Figure 32: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006-2017 81
Figure 33: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006-2017 82
Figure 34: Immunology Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 83
Figure 35: Immunology Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006-2017 84
Figure 36: Immunology Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006-2017 85
Figure 37: Immunology Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006-2017 86
Figure 38: Immunology Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017 86
Figure 39: Immunology Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006-2017 87
Figure 40: Immunology Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017 88
Figure 41: Immunology Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006-2017 89
Figure 42: Immunology Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2017 90
Figure 43: Immunology Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006-2017 91
Figure 44: Immunology Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006-2017 92
Figure 45: Immunology Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006-2017 93
Figure 46: Immunology Drugs Market, Global, Annual Revenue Forecast for Filgotinib ($m), 2019-2023 94
Figure 47: Immunology Drugs Market, Global, Annual Revenue Forecast for AR-101 ($m), 2019-2023 95
Figure 48: Immunology Drugs Market, Global, Annual Revenue Forecast for Upadacitinib ($m), 2019-2023 96
Figure 49: Immunology, Global, Annual Revenue Forecast for Lanadelumab ($m), 2018-2023 98
Figure 50: Immunology Drugs Market, Global, Annual Revenue Forecast for Ozanimod ($m), 2018-2023 99
Figure 51: Immunology Drugs Market, Global, Annual Revenue Forecast for Risankizumab ($m), 2018-2023 100
Figure 52: Immunology Drugs Market, Global, Market Size ($bn), 2016-2023 102
Figure 53: Immunology Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2016-2023 104
Figure 54: Immunology Drugs Market, Global, Annual Revenue Forecast for Cytokines and Cytokine Receptors ($bn), 2016-2023 107
Figure 55: Immunology Drugs Market, Global, Annual Revenue Forecast for Intracellular Signal Transducers ($bn), 2016-2023 108
Figure 56: Immunology Drugs Market, Global, Annual Revenue Forecast for Cell Surface Antigens ($bn), 2016-2023 109
Figure 57: Immunology Drugs Market, Global, Annual Revenue Forecast for Intercellular Interaction and Adhesion Molecules ($bn), 2016-2023 110
Figure 58: Immunology Drugs Market, Global, Company Analysis Matrix, 2016-2023 111
Figure 59: Immunology Drugs Market, Global, Cluster by Growth and Market Share, 2016-2023 112
Figure 60: Immunology Drugs Market, Global, Forecast Market Share by Company (%), 2016-2023 116
Figure 61: Immunology Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023 117
Figure 62: Immunology Drugs Market, Global, Revenues by Route of Acquisition, 2016-2023 118
Figure 63: Immunology Drugs Market, Global, AbbVie, Annual Revenue Forecast ($bn), 2016-2023 119
Figure 64: Immunology Drugs Market, Global, Johnson & Johnson, Annual Revenue Forecast ($bn), 2016-2023 120
Figure 65: Immunology Drugs Market, Global, Novartis Annual Revenue Forecast ($bn), 2016-2023 121
Figure 66: Immunology Drugs Market, Global, Pfizer, Annual Revenue Forecast ($bn), 2016-2023 123
Figure 67: Immunology Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2016-2023 124
Figure 68: Immunology Drugs Market, Global, Amgen, Annual Revenue Forecast ($bn), 2016-2023 125
Figure 69: Immunology Drugs Market, Global, Celgene, Annual Revenue Forecast ($bn), 2016-2023 126
Figure 70: Immunology Drugs Market, Global, Eli Lilly, Annual Revenue Forecast ($bn), 2016-2023 127
Figure 71: Immunology Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Company Type, 2018 128
Figure 72: Immunology Drugs Market, Global, Pipeline, High-Activity and Late-Stage Pipeline Developers by Level of Specialization, 2018 129

Companies Covered

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".